Digitisation | April 04, 2024
Aurigene introduces AI/ML assisted drug discovery platform
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Lokavant provides clinical trial intelligence
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
